Morphine (Sulfate) Lavoisier (Morphine Sulfate)

Morphine is an opioid analgesic used to manage pain across several clinical pathways.

• Severe acute pain: delivers rapid, strong analgesia for trauma, injury or major surgical procedures.
• Cancer‑related pain: controls persistent, moderate to severe pain associated with malignant disease.
• Post‑operative pain: provides effective relief during the immediate recovery period after surgery.
• Chronic non‑cancer pain: may be employed when other analgesics are insufficient, under strict medical supervision.

• Morphine acts as a full agonist at μ‑opioid receptors in the central nervous system. Binding to these G‑protein‑coupled receptors inhibits adenylate cyclase activity, reduces calcium influx, and increases potassium efflux, leading to decreased neuronal excitability and diminished transmission of nociceptive signals, thereby producing analgesia and sedation.

Morphine can cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset common after administration.
• Constipation: reduced bowel motility leading to hard stools.
• Drowsiness or sedation: central nervous system depression.
• Pruritus: itching, especially after epidural or intrathecal use.
• Sweating: increased perspiration without exertion.
• Dry mouth: reduced salivation causing discomfort.

Serious or Rare Side Effects

• Respiratory depression: markedly reduced breathing effort, potentially fatal.
• Severe hypotension: sudden drop in blood pressure, especially with rapid IV bolus.
• Addiction, dependence, or misuse: risk of tolerance and compulsive use.
• Adrenal insufficiency: impaired cortisol response in chronic therapy.
• Anaphylaxis or severe allergic reaction: rare but requires immediate intervention.

Morphine requires careful monitoring and adherence to safety guidelines.

• Assess pain level and opioid tolerance before initiating therapy.
• Avoid use in patients with significant respiratory compromise or untreated obstructive sleep apnea.
• Monitor for signs of sedation, hypotension, and gastrointestinal stasis.
• Adjust dose in renal or hepatic impairment to prevent accumulation.
• Store below 25°C: keep in the original vial, protect from light and moisture.

Morphine interacts with several drug classes that can amplify or modify its effects.

Major Interactions (Avoid)

• Central nervous system depressants (e.g., benzodiazepines, barbiturates): may cause profound sedation or respiratory depression.
• Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome and severe hypotension.
• Other opioids or opioid‑containing products: additive respiratory depression.
• Alcohol: enhances sedative and respiratory effects.
• Respiratory depressants (e.g., anesthetic gases): potentiate breathing suppression.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise morphine plasma levels.

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic efficacy.
• Diuretics: can exacerbate orthostatic hypotension.
• Anticholinergic agents: increase risk of constipation and urinary retention.
• Antidepressants (e.g., SSRIs, SNRIs): may heighten serotonin syndrome risk when combined with MAOIs.